
==== Front
Heliyon
Heliyon
Heliyon
2405-8440
Elsevier

S2405-8440(24)13881-9
10.1016/j.heliyon.2024.e37850
e37850
Research Article
A pilot pharmacokinetic and Metabolite identification study of Erinacine A in a Single landrace pig model
Chen Ying-Yu a1
Lin Ting-Wei a1
Li I-Chen a
Tsung Lin b
Hou Chun-Hsiang b
Yang Chi-Yu b
Li Tsung-Ju tsungju.li@grapeking.com.tw
a⁎
Chen Chin-Chu gkbioeng@grapeking.com.tw
acde⁎⁎
a Biotech Research Institute, Grape King Bio Ltd., Taoyuan 325, Taiwan
b GLP Animal Laboratory, Agricultural Technology Research Institute, Hsinchu 300, Taiwan
c Institute of Food Science and Technology, National Taiwan University, Taipei 106, Taiwan
d Department of Bioscience Technology, Chung Yuan Christian University, Taoyuan 320, Taiwan
e Department of Food Science, Nutrition and Nutraceutical Biotechnology, Shih Chien University, Taipei 104, Taiwan
⁎ Corresponding author. tsungju.li@grapeking.com.tw
⁎⁎ Corresponding author. Biotech Research Institute, Grape King Bio Ltd., Taoyuan 325, Taiwan. gkbioeng@grapeking.com.tw
1 These authors contributed equally to work.

11 9 2024
30 9 2024
11 9 2024
10 18 e3785019 2 2024
29 8 2024
11 9 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Erinacine A has been proven to have the ability to protect nerves and have the benefit of neurohealth. However, the pharmacokinetic and metabolites study of erinacine A in pigs, whose physiology and anatomy are similar to humans, have not been reported. In this study, 5 mg/kg of erinacine A was intravenously administered to the landrace pig. Blood, cerebrospinal fluid, and brain tissue samples were collected and analyzed by HPLC-QQQ/MS and UPLC-QTOF/MS. The results indicated the following pharmacokinetic parameters in plasma samples: with an area under the plasma concentration versus time curve (AUC) were 38.02 ± 0.03 mg∙min/L (AUC0-60) and 43.60 ± 0.06 mg∙min/L (AUC0-∞), clearance (CL) was 0.11 ± 0.00 L/min∙kg, volume of distribution (Vd) was 4.24 ± 0.00 L/kg, and terminal half-life (T1/2β) was 20.85 ± 0.03 min. In the cerebrospinal fluid samples, erinacine A was detected after 15 min and the highest concentration (5.26 ± 0.58 μg/L) was observed at 30 min. In the brain tissue sample, 77.45 ± 0.58 μg/L of erinacine A was found. In the study of metabolites, there were 6 identical metabolites in plasma and brain tissue. To our surprise, erinacine B was found to be the metabolite of erinacine A, and its concentration increased over time as erinacine A was metabolized. In summary, this study is the first to demonstrate that erinacine A can be found in the cerebrospinal fluid of landrace pigs. Additionally, the metabolite identification of erinacine A in landrace pigs is also investigated.

Graphical abstract

Image 1

Highlights

• First study to detect erinacine A in pig’s cerebrospinal fluid and brain, demonstrating its ability to cross the blood-brain barrier.

• Erinacine B, identified as erinacine A's metabolite in blood, showed increasing concentration as erinacine A metabolized.

• The confirmation of erinacine B as erinacine A's metabolite was achieved through MS/MS analysis, GNPS analysis, and a correlation study.

Keywords

Erinacine A
Erinacine B
Landrace pig
Nerve growth factor
Blood-brain barrier
Pharmacokinetic
Metabolite
==== Body
pmc1 Introduction

Erinacines, which are isolated from Hericium erinaceus mycelia, are natural products with cyathin diterpenoid as a core structure. Most erinacines have been reported to have the ability to induce the synthesis of nerve growth factor (NGF) and have the benefit of protecting nerve [[1], [2], [3], [4]]. Among erinacines, erinacine A not only can stimulate the synthesis of nerve growth factor but also increase catecholamine content in the central nervous system of rats [5]. In the light of this, there is an increasing amount of research studies on the impact of erinacine A on neurohealth.

In addition to neuroprotection [[6], [7], [8], [9]], erinacine A can also ameliorate neurodegenerative diseases [[10], [11], [12]] and possess anti-aging [[13], [14], [15]], anti-cancer [16], anti-oxidant [17], and anti-depression [18]. In the latest study, Hsu et al. reported that erinacine A can protect retinal ganglion cell morphometry and retain the visual function of traumatic optic neuropathy in the optic nerves crushed rat model by suppressing apoptosis, neuroinflammation, and oxidative stress [19].

Bioavailability, tissue distribution, and protein binding of erinacine A in Sprague-Dawley rats have been reported in previous studies [20]. The results showed that the absolute bioavailability of erinacine A was 24.39 %. In the tissue distribution experiment, erinacine A was observed in eight organs including stomach, small intestine, large intestine, liver, heart, lung, kidney, and brain. Moreover, this study is the first time to prove that erinacine A can penetrate the blood-brain barrier of rats by passive diffusion. However, there is currently no animal experimental model with physiology and anatomy similar to that of humans to confirm whether erinacine A is capable of penetrating the blood-brain barrier.

Compared with other established animal models, pigs have similarities to humans with regard to genetics, anatomy, physiology, and biochemistry including the cardiovascular system, gastrointestinal tract, liver, adrenals, skin, and kidney [[21], [22], [23]]. Because of these features, minipigs, as a non-rodent model, have been used for regulatory toxicity testing nowadays [24]. Moreover, pigs as an animal model in pharmacokinetic studies of potential drugs have been reported, such as anti-bacterial [[25], [26], [27], [28]], anti-virus [29], anti-cancer [30], pediatric drug [31], inner ear drug [32], and so on. Apart from small molecules, macromolecules are also investigated in pharmacokinetic studies in pigs’ model [33,34].

In this study, the landrace pig was used as an animal model to examine the pharmacokinetics and metabolites of erinacine A. Erinacine A was intravenously administered to the landrace pig. Blood and cerebrospinal fluid samples were collected at various time points. These samples were quantified by HPLC-QQQ/MS. Metabolites of plasma samples were identified by UPLC-QTOF/MS. Finally, after the landrace pig was sacrificed, erinacine A and its metabolites were quantified and identified in the brain tissue sample.

2 Materials and methods

2.1 Materials and reagents

Hericium erinaceus strain (BCRC 35669) was obtained from the Bioresources Collection and Research Center in Food Industry Research and Development Institute, Hsinchu, Taiwan. Ammonium acetate solution (BioUltra, for molecular biology, ∼5 M in H2O) was obtained from Merck (Darmstadt, Germany); acetonitrile (LC-MS grade) and formic acid (FA, LC-MS grade, 98 % purity) were obtained from Honeywell (Honeywell Burdick and Jackson, Muskegon, MI, USA).

2.2 Preparation of erinacine A

The Hericium erinaceus strain was first grown in an ager slant before being transferred to a potato dextrose ager plate at 26 °C for 15 days. After 15 days, the Hericium erinaceus cultures were transferred to 2-L flasks containing 1.3 L of liquid medium. The liquid culture was shaken at 120 rev/min 25 °C for 5 days. Then the flasks were scaled up to 500-L and 20-ton fermenters for 5 days and 12 days, respectively. The pH of the culture medium is 4.5 and contains 4.5 % glucose, 0.5 % soybean powder, 0.25 % yeast extract, 0.25 % peptone, and 0.05 % MgSO4. Finally, the Hericium erinaceus mycelia were harvested at the end of the 20-ton fermentation process. These raw materials were lyophilized, grounded in powder, and stored in a desiccator. Erinacine A was then extracted from the Hericium erinaceus mycelia containing 5 mg/g and purified through column chromatography to obtain purity of 99 % [35].

2.3 Animals

The care of the landrace pig and the experimental protocols used in this study were approved by the Institutional Animal Care and Use Committee of Agricultural Technology Research Institute, Hsinchu, Taiwan (IACUC#111022). The landrace pig was housed in a controllable breeding room. The room temperature was maintained at 18–26 (±2) °C and relative humidity was between 30 and 70 % with a 12-h light and dark cycle.

2.4 Pharmacokinetic study

Erinacine A was dissolved in DMSO and diluted in PBS. When the landrace pig weight about 120 kg, the drug solutions were intravenous injection to ear vein at a dose of 5 mg/kg. Blood and cerebrospinal fluid samples were collected prior to treatment administration (0 min) and at 5, 15, 30, 60 min. Blood samples were collected into K2 EDTA blood collection tubes (BD) and thoroughly mixed for 10 min. Subsequently, the samples were centrifuged at 1811×g for 15 min. The supernatant was collected and stored at −30 °C. Cerebrospinal fluid samples were collected from the landrace pig with the aid of X-ray imaging to ensure precise localization. A lumbar puncture needle was then inserted to the appropriate depth for cerebrospinal fluid collection. The cerebrospinal fluid was directly aspirated through the needle. After collection, the samples were immediately stored at −30 °C. For sample preparation, the plasma (100 μL) or cerebrospinal fluid (100 μL) was mixed with 400 μL of acetonitrile. The mixture was vortexed and centrifuged at 13,523×g for 10 min. The supernatant was collected and ready for used. The concentration of erinacine A in plasma and cerebrospinal fluid were quantified by high-performance liquid chromatography/triple quadrupole mass spectrometry (HPLC-QQQ/MS).

2.5 Metabolic study

Blood samples’ preparation was mentioned as above. For the brain tissue sample, the landrace pig was sacrificed after sampling at 60 min. After euthanized and exsanguinated the landrace pig, a small portion of brain tissue was sampled using an 8 mm biopsy punch and stored at −30 °C immediately. For sample preparation, the brain tissue sample was washed by 0.9 % NaCl before homogenization. Then, the homogenates (100 μL) were mixed with 400 μL of acetonitrile. The mixture was vortexed and centrifuged at 13,523×g for 10 min. The supernatant was collected and ready for used. The metabolites of blood samples and the brain tissue sample were identified by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS).

2.6 HPLC-QQQ/MS analysis

High-performance liquid chromatography/triple quadrupole mass spectrometry (HPLC-QQQ/MS) for quantitative analysis of erinacine A was performed on an Agilent 1100 series HPLC system (Agilent, Waldbronn, Germany) coupled with an API 3000 triple quadrupole mass spectrometer (Applied Biosystems, Concord, Ontario, Canada). A turbo ionspray electrospray ionization (ESI) interface in positive ionization mode was used. Chromatographic separation was carried out in an Agilent Eclipse XDB-C18 (3.5 μm, 4.6 × 100 mm). The column temperature was maintained at 22 °C. The mobile phase consisted of water (A) and acetonitrile (B) with gradient elution as follows: 0 min, 70 % B; 0–5 min, 70–100 % B; 5–8 min, 100%B; 8–8.1 min, 100-70 % B; 8.1–11 min, 70 % B. The flow rate was 350 μL/min and injection volume was 10 μL. Mass spectrometric detection was conducted in multiple reaction monitoring (MRM) mode with parameters as follows: ion source voltage, +4500V; ion source temperature, 350 °C; nebulizer gas, 8 psi; curtain gas, 7 psi; collision gas, 7 psi; dwell time, 200 ms. The specific precursor to product ion transitions of erinacine A is 433.2 → 301.2. Data analysis was performed with Analyst 1.4.2 software (Applied Biosystems, Concord, ON, Canada). The analysis method of HPLC-QQQ/MS has been reported in previous studies [20,36].

2.7 UPLC-QTOF/MS analysis

Ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS) for erinacine A's metabolites identification was performed on an Agilent 1290 Inifinity II UPLC system (Agilent, Palo Alto, CA, USA) coupled with an Agilent 6546 quadrupole time-of-flight mass spectrometer (Agilent, Palo Alto, CA, USA) which equipped with an electrospray ionization (ESI) source. Chromatographic separation was carried out in a Phenomenex Kinetex C18 LC Column (1.7 μm, 3.0 × 100 mm). The column temperature was maintained at 40 °C. The mobile phase A consisted of water with 0.1 % (v/v) formic acid in positive mode, 0.1 % (v/v) formic acid and 10 mM ammonium acetate in negative mode. The mobile phase B was acetonitrile. The gradient elution with a 3-min post-time was as follows: 0–0.5 min, 5 % B; 0.5–1 min, 5–20 % B; 1–6 min, 20–50 % B; 6–16 min, 50–100 % B; 16–22 min, 100 % B. The flow rate was 400 μL/min and injection volume was 2 μL. Mass spectrometric detection was conducted in multiple reaction monitoring (MRM) mode with parameters as follows: ion source voltage (ESI+/ESI−), +4000V/-3000V; gas temperature, 320 °C; drying gas flow rate, 8 L/min; nebulizer pressure, 45 psi; sheath gas temperature, 350 °C; sheath gas flow rate. 12 L/min; collision energy, 10, 20, 40, 60 V. Metabolites were identified using Agilent MassHunter Biotransformation software (version B.04.00) (Santa Clara CA, USA). Chromatograms and mass spectra of the parent and identified metabolites were extracted using Agilent MassHunter Qualitative Analysis software (version B.05.00) (Santa Clara, CA, USA). The analysis method of UPLC-QTOF/MS has been reported in previous studies [36].

2.8 Data analysis

All experimental data were presented as mean ± standard deviation (STD) of triplicate measurements. Elimination rate constant (kel) was derived from the regression equation of plasma concentration versus time curve of erinacine A. The area under the plasma concentration versus time curve of erinacine A (AUC) was calculated by the trapezoidal method. Terminal half-life (T1/2β), clearance (CL), and volume of distribution (Vd) were calculated by equation 0.693/kel, dose/AUC0-∞ and dose/C5 respectively.

3 Results and discussion

3.1 Pharmacokinetic of erinacine A in blood samples

Erinacine A in blood samples at different time points were quantified by HPLC-QQQ/MS. The results were shown in Fig. 1. Blood sample at 0 min was also analyzed and erinacine A was not observed before landrace pig was intravenously administered (data not shown). According to the regression equation, elimination rate constant (kel) was 0.033 ± 0.00. Terminal half-life (T1/2β), AUC0-60, AUC0-∞, clearance (CL), and volume of distribution (Vd) were calculated by the equation mentioned in Section 2.7, and the results were 20.85 ± 0.03 min, 38.02 ± 0.03 mg∙min/L, 43.60 ± 0.06 mg∙min/L, 0.11 ± 0.00 L/kg/min, and 4.24 ± 0.00 L/kg respectively. These pharmacokinetic parameters were summarized in Table 1. However, only one pig was treated in this study, so the data should be seen as preliminary.Fig. 1 Plasma concentration versus time curve of erinacine A in the landrace pig after intravenous administration of erinacine A at 5 mg kg−1 BW.

Fig. 1

Table 1 Pharmacokinetic Parameters of erinacine A in the landrace pig after intravenous administration of erinacine A at 5 mg kg−1 BW.

Table 1PK Parameters	Intravenous	Unit	
kel	0.033 ± 0.00	–	
T1/2β	20.85 ± 0.03	min	
AUC0-60	38.02 ± 0.03	mg·min·L−1	
AUC0-∞	43.60 ± 0.06	mg·min·L−1	
CL	0.11 ± 0.00	L·kg−1·min−1	
Vd	4.24 ± 0.00	L·kg−1	

We compared erinacine A with other central nervous drugs, which were also intravenously administered to the pigs, and summarized the pharmacokinetic parameters in Table 2. The terminal half-life of erinacine A in blood was shorter than other central nervous drugs. It was only 8 min longer than Δ9-tetrahydrocannabinol (THC). The results showed that the time of metabolic process in blood of erinacine A was faster than other central nervous drugs. Besides, the clearance of erinacine A was the highest. Aarati Rai et al. reported that pig's weight and clearance had a positive correlation when intravenously administered the same dose of morphine to the different weight of piglets [37]. In other words, the clearance was higher when the piglet was heavier. Based on this result, 120 kg of landrace pig studied in this research was the heaviest, so the clearance is the highest was predictable. Furthermore, we observed that the longer of the terminal half-life, the lower of the clearance. We also observed that the volume of distribution of erinacine A was the highest which means erinacine A was prior to leaving the plasma and entering the extravascular compartments (interstitial compartment) of the body. As a non-polar molecule, erinacine A has a tendency for lipid solubility, which allows for easier diffusion through plasma.Table 2 Pharmacokinetic study of erinacine A compared with central nervous system drugs in pigs.

Table 2Drug	Breed	Body weight (kg)	Dose (mg·kg−1)	T1/2β (min)	CL (mL·kg−1·min−1)	Vd (L·kg−1)	Reference	
erinacine A	Landrace	120	5	21	115	4.24	This study	
amoxycillin	Landrace x
Large White	78–82	20	203	5	1.07	[38]	
Δ9-tetrahydrocannabinol	Swabian
Hall male	47.7 (mean)	0.2	13	43	0.30	[39]	
deoxynivalenol	Yorkshire	20–26	1	66	–	1.13	[40]	
Lidocaine	Landrace	1–2.5	2	160	4	0.74	[41]	

3.2 Quantification of erinacine a in cerebrospinal fluid samples and brain tissue

Erinacine A in cerebrospinal fluid samples at different time points and the brain tissue sample were quantified by HPLC-QQQ/MS. According to the results, erinacine A entered into the cerebrospinal fluid at about 10 min (Fig. 2). The highest concentration of erinacine A was observed at 30 min, which was 5.26 ± 0.58 μg/L (Table 3). After that, erinacine A was decreased over time. In the brain tissue sample, 77.45 ± 0.58 μg/L of erinacine A was found (Table 3).Fig. 2 Cerebrospinal fluid concentration versus time curve of erinacine A in the landrace pig after intravenous administration of erinacine A at 5 mg/kg BW.

Fig. 2

Table 3 Concentration of erinacine A in cerebrospinal fluid samples and brain tissue after intra-venous administration of erinacine A at 5 mg/kg BW.

Table 3Time (min)	Cerebrospinal fluid (μg/L)	Brain tissue (μg/L)	
5	0.00	–	
15	0.56	–	
30	5.26	–	
60	1.66	–	
sacrificed	–	77.45	
Data expressed as means.

The central nervous system (CNS) in brain is not only protected by the meninges but also protected by blood-meningeal barrier (BMB), blood-brain barrier (BBB), and blood-cerebrospinal fluid (CSF) barrier (BCB) [42]. If the molecules want to enter the microenvironment of brain, they must pass through these natural barriers. Among of them, after the drugs pass through the blood-brain barrier, they will cross the ependymal or across the pia-glial membranes at the surface of the brain and spinal cord and then get into cerebrospinal fluid [43].

Tsai et al. have been reported that erinacine A is observed in the brain tissue of Sprague-Dawley rats after oral administration of 2.381 g/kg BW of Hericium erinaceus mycelia extract (equivalent to 50 mg/kg BW of erinacine A) to the rats [20]. In addition, they also demonstrate that erinacine A can penetrate the blood-brain barrier by passive diffusion for the first time. However, there is no further evidence to prove that erinacine A could get into the cerebrospinal fluid after it passed through the blood-brain barrier.

For this study, it is the first to observe that erinacine A was found in cerebrospinal fluid and brain tissue of landrace pigs. The results showed that erinacine A indeed crossed the blood-brain barrier and entered into the cerebrospinal fluid by following route. After 5 mg/kg BW of erinacine A was intravenously administered to the landrace pig, erinacine A would first penetrate the blood-brain barrier to the brain tissue. Then, it would get into cerebrospinal fluid by passing through the ependymal or the pia-glial membranes at the surface of the brain and spinal cord.

3.3 Metabolites identification of erinacine A

The metabolites of erinacine A in blood and brain tissue were identified by UPLC-QTOF/MS. The results were shown in Table 4. There were found 24 metabolites (assigned as M1-M24) and 6 of them were also found in brain tissue. The identical metabolites in blood and brain tissue were M1 (alcohols dehydration), M2 (demethylation), M8 (glycine conjugation), M14 (2x hydroxylation and sulfation), M17 (hetero oxide reduction + hydrogenation), and M23 (demethylation + oxidation + glucuronidation). In other words, in addition to erinacine A, these 6 metabolites (M1, M2, M8, M14, M17, M23) also could enter into the brain tissue. In our previous study, liver metabolites of erinacine A in rat and human liver S9 have been already identified [36]-. Compared with that, M1 (alcohols dehydration), M2 (demethylation), and M3 (2x hydroxylation) were also identified in rat and human liver S9 (Table S1). These 3 metabolites (M1, M2, M3) may be metabolized by pig liver S9.Table 4 Metabolites of erinacine A in plasma and brain.

Table 4ID	Metabolic reaction	Formula	Exact mass	Accurate mass	Mass error (ppm)	Fragment	Plasma	Brain	
parent	Erinacine A	C25H36O6	432.2516	432.2512	0.9	171.1166, 199.1478, 255.2104, 283.2055a, 301.2162	✓	✓	
M1	Alcohols Dehydration	C25H34O5	414.2427	414.2406	2.95	119.0859a, 135.0808, 147.0656, 281.1397, 415.2491	✓	✓	
M2	Demethylation	C25H34O6	418.2357	418.2355	0.33	59.0136a, 61.9883, 107.0366, 300.0919, 329.0945	✓	✓	
M3	2x Hydroxylation	C25H36O8	464.2423	464.2410	2.75	57.0322, 119.0852, 181.0998, 209.0956, 295.9762a	✓		
M4	3x Hydroxylation	C25H36O9	480.2357	480.2359	−0.41	61.9878a, 199.0814, 282.8705, 394.9423, 534.0104	✓		
M5	2x Hydrogenation	C25H40O6	436.2821	436.2825	−0.95	61.9883, 75.0089, 146.9665, 343.9977, 495.2958a	✓		
M6	Decarboxylation	C24H36O4	388.2600	388.2614	−3.41	81.0694, 105.0699a, 107.0862, 119.0861, 159.1162	✓		
M7	Phosphorylation	C25H37O9P	512.2199	512.2175	4.66	61.9881a, 211.1131, 255.1029, 448.3075, 511.52126	✓		
M8	Glycine Conjugation	C27H39NO7	489.2721	489.2727	−1.15	76.0757a, 119.0857, 281.1371, 415.2117, 490.2796	✓	✓	
M9	Glutamine Conjugation	C30H44NO8	546.3072	546.3067	0.98	61.9882a, 89.0245, 504.3039, 528.3087, 605.3212	✓		
M10	Glucuronide Conjugation	C31H44O12	608.2805	608.2833	−4.55	70.0652a, 129.1022, 286.1379, 293.0972, 347.0118	✓		
M11	2x Sulfate Conjugation	C25H36O12S2	592.1658	592.1648	1.62	258.0061, 277.0455, 343.9966a, 459.0009, 507.9302	✓		
M12	Ethyl to Carboxylic Acid	C24H32O8	448.2103	448.2097	1.31	81.0686a, 85.0655, 151.0738, 177.0198, 185.0105	✓		
M13	Hydroxylation + Glucuronide	C31H44O13	624.2775	624.2782	−1.07	59.0133, 75.0088, 89.0242, 475.2342a, 623.2704	✓		
M14	2x Hydroxylation and Sulfation	C25H36O14S2	624.1540	624.1547	−1.06	70.0651a, 72.0808, 86.0966, 110.0712, 197.1306	✓	✓	
M15	Hydrolysis + 2x Oxidation	C25H38O9	482.2517	482.2516	0.31	61.9886, 71.0139, 146.9677, 201.0225, 541.2658a	✓		
M16	Decarboxylation and Glucuronidation	C30 H44O11	580.2876	580.2884	−1.39	59.0140, 75.0080, 113.0238, 475.2333a, 625.2858	✓		
M17	Hetero oxide reduction + Hydrogenation	C25H38O5	418.2690	418.2719	−3.12	57.0692, 86.0968a, 102.0915, 124.9982, 163.0148	✓	✓	
M18	Carboxylation + Glucuronidation	C31H42O14	638.2578	638.2575	0.53	265.1586, 277.1589, 295.1700, 313.1806a, 331.1906	✓		
M19	Oxidation + Acetylcysteination	C30H45NO10S	611.2751	611.2764	−2.15	61.9877, 146.9654, 157.9712, 174.9555a, 337.0002	✓		
M20	2x Oxidation + Glucuronidation	C31H44O14	640.2736	640.2731	0.82	83.0492, 157.1011, 239.1433, 279.1741, 297.1848a	✓		
M21	Glucuronidation + Hydrogenation	C31H46O12	610.2986	610.2989	−0.53	61.9885, 75.0082, 283.2061, 459.2397a, 609.2913	✓		
M22	Gluthation Conjugation + Hydroxylation	C35H51N3O13S	753.3113	753.3143	−3.88	70.0650, 72.0805, 86.0966, 270.1820, 623.8371a	✓		
M23	Demethylation + Oxidation + Glucuronidation	C30H42O13	610.2616	610.2625	−1.47	146.9652, 343.9979, 487.1938, 505.2089, 655.2598a	✓	✓	
M24	Erinacine B	C25H36O6	432.2515	432.2512	0.72	135.1170a, 149.1321, 183.1164, 253.1948, 283.2065	✓		
a Most abundance peak of MS/MS fragments.

To our surprise, erinacine B (M24) was one of the metabolites of erinacine A. Erinacine B, which is one of the compounds in Hericium erinaceus, also affects stimulating synthesis of nerve growth factor [44,45]. Due to the identical molecular weight of erinacine A and erinacine B, it is not possible to differentiate these two compounds based on MS results alone. However, the use of MS/MS fragments proves instrumental in identifying compounds with the same molecular weight. Table 4 and Fig. 3 showcase the MS/MS fragments and spectrum of erinacine A and erinacine B, respectively. Based on the MS/MS results, the primary fragment of erinacine A was measured at 283.2055 (Fig. 3 (a)), while erinacine B was found to be 135.1170 (Fig. 3 (b)). It is worth noting that 283.2065 was the second highest fragment observed for erinacine B. Therefore, the major MS/MS fragment enables us to differentiate between erinacine A and erinacine B. Besides, global natural products social molecular networking (GNPS) [46] showed the correlation between erinacine A and erinacine B (Fig. S1). The third evidence was that the concentration of erinacine B increased over time as erinacine A was metabolized (Fig. 4). Based on the evidence provided, it can be concluded that erinacine B is indeed a metabolite of erinacine A. However, erinacine B had not been detected in cerebrospinal fluid and brain tissue samples. Further investigation is needed by increasing the number of animals to understand how erinacine B circulates in biological systems.Fig. 3 The MS/MS spectrum of erinacine A (a) and erinacine B (b).

Fig. 3

Fig. 4 Relative concentration versus time curve of erinacine A and erinacine B in plasma after intravenous administration of erinacine A at 5 mg/kg BW in landrace pig.

Fig. 4

4 Conclusions

This is the first study to discuss pharmacokinetics and metabolites of erinacine A in landrace pigs, whose genetics, anatomy, physiology, and biochemistry are considered close to humans. According to the pharmacokinetic parameters of landrace pig after intravenous administration of erinacine A at 5 mg kg−1 BW, the terminal half-life of erinacine A in plasma was only 21 min. However, the volume of distribution of erinacine A is higher than other central nervous system drugs. This may be because erinacine A has better lipid solubility and, therefore leaves plasma more easily. This also echoes the reason for the short half-life in plasma. Apart from blood samples, erinacine A also observed in cerebrospinal fluid and brain tissue samples. After erinacine A entered into brain tissue by crossing the blood-brain barrier, it passed through the ependymal or the pia-glial membranes at the surface of the brain and spinal cord and get into cerebrospinal fluid. This is further evidence to show that erinacine A could penetrate the blood-brain barrier.

In the experiment of metabolites identification, there were 24 metabolites in plasma and 6 of them were identical in brain tissue. Among these 24 metabolites, M1 (alcohols dehydration), M2 (demethylation), and M3 (2x hydroxylation) may be metabolized by pig liver S9. In addition, there were three methods used to confirm that erinacine B, which can stimulate the growth of nerve growth factor, was the metabolite of erinacine A. The first method involved analyzing the major MS/MS fragment of erinacine A and erinacine B. The second method was the GNPS analysis of erinacine A and its metabolites. The last method involved studying the correlation between erinacine A and erinacine B during the metabolism of erinacine A. However, erinacine B was not been found in brain tissue. Whether erinacine B can enter into brain tissue still needs further investigation.

In summary, this pilot study is the first to investigate the pharmacokinetics and metabolites of erinacine A in landrace pigs. The results showed that erinacine A has a shorter terminal half-life compared with other central nervous drugs, which were intravenously administered to the pigs. However, clearance and volume of distribution of erinacine A were the highest. This study is also the first to observe erinacine A in cerebrospinal fluid and brain tissue in a non-rodent model. The findings indicated that erinacine A was able to cross the blood-brain barrier and enter the cerebrospinal fluid. Additionally, erinacine B was identified as one of the metabolites of erinacine A.

Ethics statement

The care of the landrace pig and the experimental procedures used in this study were authorized by the Institutional Animal Care and Use Committee of Agricultural Technology Research Institute, Hsinchu, Taiwan. The ethics approval number for this study is IACUC#111022.

Data availability statement

The raw materials and compounds presented in this study are available from the corresponding author upon reasonable request.

CRediT authorship contribution statement

Ying-Yu Chen: Writing – review & editing, Writing – original draft, Visualization, Formal analysis, Data curation. Ting-Wei Lin: Writing – review & editing, Writing – original draft, Project administration, Methodology, Formal analysis, Data curation. I-Chen Li: Visualization. Lin Tsung: Methodology. Chun-Hsiang Hou: Methodology. Chi-Yu Yang: Methodology. Tsung-Ju Li: Writing – review & editing, Project administration, Investigation, Conceptualization. Chin-Chu Chen: Writing – review & editing, Supervision, Resources, Investigation, Funding acquisition, Conceptualization.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Ying-Yu Chen, Ting-Wei Lin, I-Chen Li, Tsung-Ju Li, Chin-Chu Chen reports a relationship with Grape King Bio Ltd that includes: employment. Lin Tsung, Chun-Hsiang Hou, Chi-Yu Yang reports a relationship with Agricultural Technology Research Institute that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix B Supplementary data

The following is the Supplementary data to this article.Multimedia component 1

Multimedia component 1

Acknowledgment

Graphical abstract was created with BioRender.com.

Appendix B Supplementary data to this article can be found online at https://doi.org/10.1016/j.heliyon.2024.e37850.
==== Refs
References

1 Kawagishi H. Zhuang C. Yunoki R. Compounds for dementia from Hericium erinaceum Drugs Future 33 2008 149 10.1358/dof.2008.033.02.1173290
2 Lai P.L. Naidu M. Sabaratnam V. Wong K.H. David R.P. Kuppusamy U.R. Abdullah N. Malek S.N.A. Neurotrophic properties of the Lion's mane medicinal mushroom, Hericium erinaceus (Higher Basidiomycetes) from Malaysia Int. J. Med. Mushrooms 15 2013 539 554 10.1615/intjmedmushr.v15.i6.30 24266378
3 Li I.C. Lee L.Y. Tzeng T.T. Chen W.P. Chen Y.P. Shiao Y.J. Chen C.C. Neurohealth properties of Hericium erinaceus mycelia enriched with erinacines Behav. Neurol. 2018 5802632 10.1155/2018/5802634
4 Wei J. Li J.y. Feng X.l. Zhang Y. Hu X. Hui H. Xue X. Qi J. Unprecedented neoverrucosane and cyathane diterpenoids with anti-neuroinflammatory activity from cultures of the culinary-medicinal mushroom Hericium erinaceus Molecules 28 2023 6380 10.3390/molecules28176380 37687209
5 Shimbo M. Kawagishi H. Yokogoshi H. Erinacine A increases catecholamine and nerve growth factor content in the central nervous system of rats Nutr. Res. 25 2005 617 623 10.1016/j.nutres.2005.06.001
6 Lee K.F. Chen J.H. Teng C.C. Shen C.H. Hsieh M.C. Lu C.C. Lee K.C. Lee L.Y. Chen W.P. Chen C.C. Protective effects of Hericium erinaceus mycelium and its isolated erinacine A against ischemia-injury-induced neuronal cell death via the inhibition of iNOS/p38 MAPK and nitrotyrosine Int. J. Mol. Sci. 15 2014 15073 15089 10.3390/ijms150915073 25167134
7 Huang H.T. Ho C.H. Sung H.Y. Lee L.Y. Chen W.P. Chen Y.W. Chen C.C. Yang C.S. Tzeng S.F. Hericium erinaceus mycelium and its small bioactive compounds promote oligodendrocyte maturation with an increase in myelin basic protein Sci. Rep. 11 2021 6551 10.1038/s41598-021-88168-w 33753806
8 Lee S.L. Hsu J.Y. Chen T.C. Huang C.C. Wu T.Y. Chin T.Y. Erinacine a prevents lipopolysaccharide-mediated glial cell activation to protect dopaminergic neurons against inflammatory factor-induced cell death in vitro and in vivo Int. J. Mol. Sci. 23 2022 810 10.3390/ijms23020810 35054997
9 Hsu P.C. Lan Y.J. Chen C.C. Lee L.Y. Chen W.P. Wang Y.C. Lee Y.H. Erinacine A attenuates glutamate transporter 1 downregulation and protects against ischemic brain injury Life Sci. 306 2022 120833 10.1016/j.lfs.2022.120833
10 Tzeng T.T. Chen C.C. Lee L.Y. Chen W.P. Lu C.K. Shen C.C. Huang F C.Y. Chen C.C. Shiao Y.-J. Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice J. Biomed. Sci. 23 2016 49 10.1186/s12929-016-0266-z 27350344
11 Li I.C. Chang H.H. Lin C.H. Chen W.P. Lu T.H. Lee L.Y. Chen Y.W. Chen Y.-P. Chen C.C. Lin D.P.C. Prevention of early Alzheimer's disease by erinacine A-enriched Hericium erinaceus mycelia pilot double-blind placebo-controlled study Front. Aging Neurosci. 12 2020 155 10.3389/fnagi.2020.00155 32581767
12 Lee K.F. Tung S.Y. Teng C.C. Shen C.H. Hsieh M.C. Huang C.Y. Lee K.C. Lee L.Y. Chen W.P. Chen C.C. Post-treatment with erinacine A, a derived diterpenoid of H. erinaceus, attenuates neurotoxicity in MPTP model of Parkinson's disease Antioxidants 9 2020 137 10.3390/antiox9020137 32033220
13 Li I.C. Lee L.Y. Chen Y.J. Chou M.Y. Wang M.F. Chen W.P. Chen Y.P. Chen C.C. Erinacine A-enriched Hericium erinaceus mycelia promotes longevity in Drosophila melanogaster and aged mice PLoS One 14 2019 e0217226 10.1371/journal.pone.0217226
14 Lee L.Y. Chou W. Chen W.P. Wang M.F. Chen Y.J. Chen C.C. Tung K.C. Erinacine a-enriched hericium erinaceus mycelium delays progression of age-related cognitive decline in senescence accelerated mouse prone 8 (samp8) mice Nutrients 13 2021 3659 10.3390/nu13103659 34684662
15 Chan Y.C. Lin T.C. Chen C.C. Lee L.Y. Chen W.P. Liu Y.Z. Hwang J.H. Effects of erinacine A-enriched Hericium erinaceus on elderly hearing-impaired patients: a double-blind, randomized, placebo-controlled clinical trial J. Funct.Foods 97 2022 105220 10.1016/j.jff.2022.105220
16 Prasher P. Sharma M. Sharma A.K. Sharifi-Rad J. Calina D. Hano C. Cho W.C. Key oncologic pathways inhibited by Erinacine A: a perspective for its development as an anticancer molecule Biomed. Pharmacother. 160 2023 114332 10.1016/j.biopha.2023.114332
17 Hsu C.H. Liao E.C. Chiang W.C. Wang K.L. Antioxidative activities of micronized solid-state cultivated hericium erinaceus rich in erinacine A against MPTP-induced damages Molecules 28 2023 3386 10.3390/molecules28083386 37110620
18 Chiu C.H. Chyau C.C. Chen C.C. Lee L.Y. Chen W.P. Liu J.L. Lin W.H. Mong M.C. Erinacine A-enriched Hericium erinaceus mycelium produces antidepressant-like effects through modulating BDNF/PI3K/Akt/GSK-3β signaling in mice Int. J. Mol. Sci. 19 2018 341 10.3390/ijms19020341 29364170
19 Hsu C.L. Wen Y.T. Hsu T.C. Chen C.C. Lee L.Y. Chen W.P. Tsai R.K. Neuroprotective effects of erinacine A on an experimental model of traumatic optic neuropathy Int. J. Mol. Sci. 24 2023 1504 10.3390/ijms24021504 36675019
20 Tsai P.C. Wu Y.K. Hu J.H. Li I.C. Lin T.W. Chen C.C. Kuo C.F. Preclinical bioavailability, tissue distribution, and protein binding studies of erinacine A, a bioactive compound from Hericium erinaceus mycelia using validated LC-MS/MS method Molecules 16 2021 4510 10.3390/molecules26154510
21 Schook L.B. Collares T.V. Darfour-Oduro K.A. De A.K. Rund L.A. Schachtschneider K.M. Seixas F.K. Unraveling the swine genome: implications for human health Annu. Rev. Anim. Biosci. 3 2015 219 244 10.1146/annurev-animal-022114-110815 25689318
22 Tang H. Mayersohn M. Porcine prediction of pharmacokinetic parameters in people: a pig in a poke? Drug Metab. Dispos. 46 2018 1712 1724 10.1124/dmd.118.083311 30171162
23 Swindle M.M. Makin A. Herron A.J. Clubb F.J. Jr. Frazier K.S. Swine as models in biomedical research and toxicology testing Vet. Pathol. 49 2012 344 356 10.1177/0300985811402846 21441112
24 Bode G. Clausing P. Gervais F. Loegsted J. Luft J. Nogues V. Sims J. The utility of the minipig as an animal model in regulatory toxicology J. Pharmacol. Toxicol. Methods 62 2010 196 220 10.1016/j.vascn.2010.05.009 20685310
25 Eckhardt E. Li Y. Mamerow S. Schinköthe J. Sehl-Ewert J. Dreisbach J. Corleis B. Dorhoi A. Teifke J. Menge C. Pharmacokinetics and efficacy of the benzothiazinone BTZ-043 against tuberculous mycobacteria inside granulomas in the Guinea pig model Antimicrob. Agents Chemother. 67 2023 e01438 10.1128/aac.01438-22
26 Somogyi Z. Mag P. Simon R. Kerek Á. Szabó P. Albert E. Biksi I. Jerzsele Á. Pharmacokinetics and pharmacodynamics of florfenicol in plasma and synovial fluid of pigs at a dose of 30 mg/kgbw following intramuscular administration Antibiotics 12 2023 758 10.3390/antibiotics12040758 37107120
27 Yeshwante S.B. Hanafin P. Miller B.K. Rank L. Murcia S. Xander C. Annis A. Baxter V.K. Anderson E.J. Jermain B. Konicki R. Schmalstig A.A. Stewart I. Braunstein M. Hickey A.J. Rao G.G. Pharmacokinetic considerations for optimizing inhaled spray-dried pyrazinoic acid formulations Mol. Pharm. 20 2023 4491 4504 10.1021/acs.molpharmaceut.3c00199 37590399
28 Yi D. Wen X. Xu W. Xu Y. Deng X. Yan G. Wu L. Liang Q. Liang Z. Peng J. Development of an amoxicillin-radix scutellaria extract formulation and evaluation of its pharmacokinetics in pigs BMC Vet. Res. 19 2023 164 10.1186/s12917-023-03713-1 37726783
29 Schwagerle G. Sharp M.J. Parr A. Schimek D. Mautner S.I. Birngruber T. Detailed pharmacokinetic characterization of advanced topical acyclovir formulations with IVPT and in vivo Open Flow Microperfusion Int. J. Pharm. 643 2023 123269 10.1016/j.ijpharm.2023.123269
30 Requejo F. Opezzo J. Vater A. Asprea M. Lagomarsino E. Sampor C. Fandiño A. Chantada G. Francis J.H. Abramson D.H. Pharmacokinetics of orbital topotecan after ophthalmic artery chemosurgery and intravenous infusion in the swine model Invest. Ophthalmol. Vis. Sci. 64 2023 3 10.1167/iovs.64.12.3
31 Ayuso M. Buyssens L. Stroe M. Valenzuela A. Allegaert K. Smits A. Annaert P. Mulder A. Carpentier S. Van Ginneken C. The neonatal and juvenile pig in pediatric drug discovery and development Pharmaceutics 13 2020 44 10.3390/pharmaceutics13010044 33396805
32 Yildiz E. Gadenstaetter A.J. Gerlitz M. Landegger L.D. Liepins R. Nieratschker M. Glueckert R. Staecker H. Honeder C. Arnoldner C. Investigation of inner ear drug delivery with a cochlear catheter in piglets as a representative model for human cochlear pharmacokinetics Front. Pharmacol. 14 2023 1062379 10.3389/fphar.2023.1062379
33 Zheng Y. Tesar D.B. Benincosa L. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration mAbs 4 2012 243 255 10.4161/mabs.4.2.19387 22453096
34 Pedersen K.M. Gradel A.K.J. Ludvigsen T.P. Christoffersen B.Ø. Fuglsang-Damgaard C.A. Bendtsen K.M. Madsen S.H. Manfé V. Refsgaard H.H.F. Optimization of pig models for translation of subcutaneous pharmacokinetics of therapeutic proteins: liraglutide, insulin aspart and insulin detemir Transl. Res. 239 2022 71 84 10.1016/j.trsl.2021.08.005 34428585
35 Li I.C. Chen Y.L. Chen W.P. Lee L.Y. Tsai Y.T. Chen C.C. Chen C.S. Genotoxicity profile of erinacine A-enriched Hericium erinaceus mycelium Toxicol Rep 1 2014 1195 1201 10.1016/j.toxrep.2014.11.009 28962329
36 Kuo Y.H. Lin T.W. Lin J.Y. Chen Y.W. Li T.J. Chen C.C. Identification of common liver metabolites of the natural bioactive compound erinacine A, purified from Hericium erinaceus mycelium Appl. Sci. 12 2022 1201 10.3390/app12031201
37 Rai A. Bhalla S. Rebello S.S. Kastrissios H. Gulati A. Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs J. Pharm. Pharmacol. 57 2005 981 985 10.1211/0022357056505 16102253
38 Martinez‐Larranaga M.R. Anadón A. Martinez M.A. Diaz M.J. Frejo M.T. Castellano V.J. Isea G. De la Cruz C.O. Pharmacokinetics of amoxycillin and the rate of depletion of its residues in pigs Vet. Rec. 154 2004 627 632 10.1136/vr.154.20.627 15180397
39 Schaefer N. Wojtyniak J.G. Kettner M. Schlote J. Laschke M.W. Ewald A.H. Lehr T. Menger M.D. Maurer H.H. Schmidt P.H. Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology Toxicol. Lett. 253 2016 7 16 10.1016/j.toxlet.2016.04.021 27113702
40 Prelusky D. Hartin K. Trenholm H. Distribution of deoxynivalenol in cerebral spinal fluid following administration to swine and sheep J. Environ. Sci. Health. B 25 1990 395 413 10.1080/03601239009372697 2144863
41 Satas S. Johannessen S.I. Hoem N.O. Haaland K. Sorensen D.R. Thoresen M. Lidocaine pharmacokinetics and toxicity in newborn pigs Anesth. Analg. 85 1997 306 312 10.1097/00000539-199708000-00012 9249105
42 Alves de Lima K. Rustenhoven J. Kipnis J. Meningeal immunity and its function in maintenance of the central nervous system in health and disease Annu. Rev. Immunol. 38 2020 597 620 10.1146/annurev-immunol-102319-103410 32340575
43 Nau R. Sorgel F. Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections Clin. Microbiol. Rev. 23 2010 858 883 10.1128/cmr.00007-10 20930076
44 Kawagishi H. Shimada A. Shirai R. Okamoto K. Ojima F. Sakamoto H. Ishiguro Y. Furukawa S. Erinacines A. B and C, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of Hericium erinaceum Tetrahedron Lett. 35 1994 1569 1572 10.1016/S0040-4039(00)76760-8
45 Rupcic Z. Rascher M. Kanaki S. Köster R.W. Stadler M. Wittstein K. Two new cyathane diterpenoids from mycelial cultures of the medicinal mushroom Hericium erinaceus and the rare species, Hericium flagellum Int. J. Mol. Sci. 19 2018 740 10.3390/ijms19030740 29509661
46 Wang M. Carver J.J. Phelan V.V. Sharing and community curation of mass spectrometry data with global natural products social molecular networking Nat. Biotechnol. 34 2016 828 837 10.1038/nbt.3597 27504778
